TuAnalyze puts diabetes on the map
BERKELEY, Calif. A nonprofit organization’s Web site — which connects people touched by diabetes and raises diabetes awareness — and a children’s hospital have developed an app that measures and shares blood glucose levels.
Diabetes Hands Foundation’s TuDiabetes.org and Children’s Hospital Boston have launched TuAnalyze, which supports sharing of diabetes information throughout the community and feedback of community-level diabetes information to users.
How it works: the information submitted by members will be displayed in a map of the United States on the TuDiabetes network, with states lighting up according to the aggregate A1c data. Once a threshold of participants in each state is reached, the state’s color reflects whether the average A1c submitted is within the range recommended by physicians. Users can compare personal measures of diabetes to community measures on the TuAnalyze map.
“Many people are turning to the Internet for information, support, and resources to help manage their disease on a day by day basis,” said principal TuAnalyze investigator Kenneth Mandl, who also serves as a faculty member of the informatics program at Children’s Hospital Boston. “With TuAnalyze we aim to collect and share basic information people provide in a secure, structured way that will be beneficial to the community — so each member can learn more about themselves and their peers — and in a way that may inform public health endeavors and research.”
TuAnalyze was developed with support from the U.S. Centers for Disease Control and Prevention.
Axellia acquires OTC maker
COPENHAGEN Axellia Pharmaceuticals on Tuesday announced its acquisition of the Phoenix Global Supply Group, based in White Plains, N.Y., to supply over-the-counter topical anti-infectives to the U.S. and Canadian markets.
“An important part of our strategy is to expand our offering to include finished products in targeted dosage forms and geographic markets,” said Axellia CEO Carl-Ake Carlsson, “while continuing to develop our core active pharmaceutical ingredients business.”
Phoenix’s initial product launches in North America are expected to include private-label offerings around bacitracin and polymyxin B sulfate, two of the major ingredients found in topical anti-infective first aid products.
“The Phoenix team is delighted to welcome Axellia as its majority owner. While there are many other manufacturers of over-the-counter antibiotic products, we believe that the U.S. and Canadian markets for these products continue to be attractive and provide a significant opportunity for Phoenix,” stated Walter Jenkins, Phoenix CEO.
NAD recommends InflameAway Celadrin ad claims be discontinued
NEW YORK The National Advertising Division of the Council of Better Business Bureaus on Wednesday recommended that Imagenetix discontinue certain advertising claims made for the dietary supplement InflameAway Celadrin following a challenge by Schiff Nutrition Group. InflameAway executives countered that they did not agree with the decision, but agreed to abide by NAD’s suggestions.
Imagenetix, at the outset of the NAD review, informed the bureau that the company had been revising its marketing campaign prior to the NAD challenge and had discontinued all of its comparative claims versus glucosamine/chondroitin (and other joint health products), as well as its claim that Celadrin has been “proven to work.”
NAD advised Imagenetix to also discontinue the claim that Celadrin is “clinically tested and shown to be effective for improving joint comfort” as the evidence in the record was inconsistent and insufficient to support a claim that either Celadrin, or its active ingredient, cetylated fatty acid, had been proven effective through clinical trial.
Further, NAD noted, while the patent on the ingredient is evidence of its novelty, the patent alone cannot support a “clinically shown” claim. NAD recommended that the advertiser discontinue the claim.
NAD also found that the claim that “patented InflameAway Celadrin is a medical breakthrough,” was not supported by the research on Celadrin or by the patent on the key ingredient in Celadrin and recommended that it be discontinued.
InflameAway, in its advertiser’s statement, said it is “extremely disappointed that the unrebutted opinions of two highly qualified scientific experts have been rejected in favor of the non-scientific judgment made by NAD counsel.”
However, in the spirit of cooperation, the company said it “has and will continue to voluntarily discontinue the use of all NAD challenged claims in its national advertising.”